Status
Completed
Phase
Not applicable
Enrollment
216,155
Locations
1
Results
Not posted
Publications
0
Study summary
Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. The investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. The investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.
Osteoporotic fracture has become a serious health and economic burden as life expectancy increases. In a WHO report, the burden of osteoporotic fractures in 2002 was 2.8 million disability-adjusted life years, which is more than that for hypertension and slightly less than that for diabetes mellitus or chronic obstructive pulmonary diseases. Many patients who have had a diagnosed fracture have never been diagnosed with osteoporosis, therefore, closing the gap in osteoporosis treatment is important. This situation is primarily due to the fact that osteoporosis symptoms are often not recognized until a fracture occurs. Osteoporotic fractures, especially those of the hip and vertebral, are associated with an increased risk of death. Early detection of high risk for osteoporotic fractures is important; however, post-fracture management, especially interventions intended to lower mortality, is an emerging public health issue in rapidly aging societies. The burden of osteoporotic fracture is higher than that of hypertension, however, osteoporosis is always given less attention than other chronic diseases by health professionals and the general population.
Interventions
DRUG
Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
Timeline
First posted
May 9, 2022
Study start
Nov 1, 2020
Primary completion
Sep 30, 2021
Study completion
Oct 31, 2021
Results posted
Not reported
Registry updated
Apr 4, 2023
Outcomes
Number of deaths with and without anti-osteoporotic therapy after hip fracture surgery
Time frame · 12 years
This is the number of participants who died during the time of observation from Taiwan's National Health Insurance Research Database.
Number of deaths with or without anti-osteoporosis therapy after hip or vertebral fracture surgery among older adults
Time frame · 12 years
This is the number of participants who died during the time of observation from Taiwan's National Health Insurance Research Database.
Number of deaths with and without bisphosphonates after hip or spine fracture surgery
Time frame · 12 years
This is the number of participants who died during the time of observation from Taiwan's National Health Insurance Research Database.
Number of deaths with different types of anti-osteoporosis treatments after post-fracture
Time frame · 12 years
This is the number of participants who died during the time of observation from Taiwan's National Health Insurance Research Database.
Number of deaths in five leading causes of death with and without anti-osteoporosis treatment after post-fracture
Time frame · 12 years
This is the number of participants who died during the time of observation from Taiwan's National Death Registry. The five leading causes are defined as the main five leading causes.
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Newly diagnosed osteoporosis and hip fracture are defined as a claim record from the NHIRD between 2009 and 2017. Exclusion Criteria: * Patients with a diagnosis of osteoporosis or osteoporotic fractures in 2008 or before were excluded.
Study locations
Taiwan. Showing up to 24 locations stored in the fast local snapshot.
Department of Family Medicine, National Cheng Kung Univ Hosp
Tainan, Taiwan
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Migraine · Headache
Not applicable
Completed
513
2026-07
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
Jordan University of Science and Technology · Root Canal Treatment · Postoperative Pain
Not applicable
Active, not recruiting
75
2026-07
Tanta University · Calcitonin · Subcutaneous
Phase 3
Recruiting
168
2026-07
Insel Gruppe AG, University Hospital Bern · Acute Mountain Sickness
Phase 4
Not yet recruiting
30
2026-07
Institut Claudius Regaud · Medullary Thyroid Cancer
Not applicable
Completed
24
2026-06
Rigmor Højland Jensen · Idiopathic Intracranial Hypertension (IIH)
Phase 3
Not yet recruiting
96
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.